secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2024-07-29T23:59:59+00:00
Accession:  0001104659-24-083126
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 2.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium to acquire Ironshore Therapeutics for $525M; Jornay PM ADHD drug; Q2 prelim rev $145M
--------------------------------------------------------------------------------

- Acquires Ironshore for $525M cash plus up to $25M milestone if Jornay PM net revenue exceeds defined 2025 threshold.
- Jornay PM (ADHD) expected >$100M net revenue in 2024; H1 2024 prescriptions up 32% YoY.
- Funded by cash on hand and new $646M five-year Pharmakon loan with 300bps rate reduction.
- Preliminary Q2 2024 net product revenue $145M (+7% YoY); reaffirms FY2024 guidance of $580-595M revenue, $380-395M adj EBITDA.
- Director Neil McFarlane resigned immediately due to conflict of interest (CEO of Zevra Therapeutics).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924083126/0001104659-24-083126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924083126/tm2420341d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-083126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer